nct_id,nlm_download_date_description,study_first_submitted_date,results_first_submitted_date,disposition_first_submitted_date,last_update_submitted_date,study_first_submitted_qc_date,study_first_posted_date,study_first_posted_date_type,results_first_submitted_qc_date,results_first_posted_date,results_first_posted_date_type,disposition_first_submitted_qc_date,disposition_first_posted_date,disposition_first_posted_date_type,last_update_submitted_qc_date,last_update_posted_date,last_update_posted_date_type,start_month_year,start_date_type,start_date,verification_month_year,verification_date,completion_month_year,completion_date_type,completion_date,primary_completion_month_year,primary_completion_date_type,primary_completion_date,target_duration,study_type,acronym,baseline_population,brief_title,official_title,overall_status,last_known_status,phase,enrollment,enrollment_type,source,limitations_and_caveats,number_of_arms,number_of_groups,why_stopped,has_expanded_access,expanded_access_type_individual,expanded_access_type_intermediate,expanded_access_type_treatment,has_dmc,is_fda_regulated_drug,is_fda_regulated_device,is_unapproved_device,is_ppsd,is_us_export,biospec_retention,biospec_description,ipd_time_frame,ipd_access_criteria,ipd_url,plan_to_share_ipd,plan_to_share_ipd_description,created_at,updated_at,days_since_update
NCT04276896,"ClinicalTrials.gov processed this data on September 30, 2020",2020-02-17,NA,NA,2020-03-17,2020-02-17,2020-02-19,Actual,NA,NA,NA,NA,NA,NA,2020-03-17,2020-03-19,Actual,"March 24, 2020",Anticipated,2020-03-24,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Phase I/II Multicenter Trial of Lentiviral Minigene Vaccine (LV-SMENP) of Covid-19 Coronavirus,Recruiting,NA,Phase 1/Phase 2,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:58:42Z,2020-10-01T09:58:42Z,210
NCT04283461,"ClinicalTrials.gov processed this data on September 30, 2020",2020-02-21,NA,NA,2020-07-16,2020-02-21,2020-02-25,Actual,NA,NA,NA,NA,NA,NA,2020-07-16,2020-07-17,Actual,"March 16, 2020",Actual,2020-03-16,"May 26, 2020",2020-05-26,"November 22, 2021",Anticipated,2021-11-22,"November 22, 2021",Anticipated,2021-11-22,NA,Interventional,NA,,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Phase I, Open-Label, Dose-Ranging Study of the Safety and Immunogenicity of 2019-nCoV Vaccine (mRNA-1273) in Healthy Adults","Active, not recruiting",NA,Phase 1,120,Actual,National Institute of Allergy and Infectious Diseases (NIAID),,13,NA,NA,FALSE,NA,NA,NA,NA,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,NA,NA,2020-10-01T09:57:59Z,2020-10-01T09:57:59Z,89
NCT04299724,"ClinicalTrials.gov processed this data on September 30, 2020",2020-03-05,NA,NA,2020-03-06,2020-03-06,2020-03-09,Actual,NA,NA,NA,NA,NA,NA,2020-03-06,2020-03-09,Actual,"February 15, 2020",Actual,2020-02-15,March 2020,2020-03-31,"December 31, 2024",Anticipated,2024-12-31,"July 31, 2023",Anticipated,2023-07-31,NA,Interventional,NA,,Safety and Immunity of Covid-19 aAPC Vaccine,Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine,Recruiting,NA,Phase 1,100,Anticipated,Shenzhen Geno-Immune Medical Institute,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:55:56Z,2020-10-01T09:55:56Z,221
NCT04313127,"ClinicalTrials.gov processed this data on September 30, 2020",2020-03-15,NA,NA,2020-05-16,2020-03-17,2020-03-18,Actual,NA,NA,NA,NA,NA,NA,2020-05-16,2020-05-19,Actual,"March 16, 2020",Actual,2020-03-16,May 2020,2020-05-31,"December 20, 2022",Anticipated,2022-12-20,"December 30, 2020",Anticipated,2020-12-30,NA,Interventional,CTCOVID-19,,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"A Single-center,Open-labelï¼ŒDose-escalating Phase I Clinical Trial to Evaluate Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Healthy Adults Aged 18-60 Years Old","Active, not recruiting",NA,Phase 1,108,Actual,CanSino Biologics Inc.,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,Data will be available beginning 3 months and ending one year following article publication,"Data access requests will be reviewed by the sponsorï¼Œinvestigator and collaborators on the basis of scientific merit. To gain access, data requestors will need to sign a data access agreement.",http://www.jshealth.com/,Yes,"We support data sharing of the individual participant data. The individual participant data that underlie the results reported in this article, after deidentiï¬cation (text, tables, figures, and appendixes) will be shared. Individual participant data will be available beginning 3 months and ending one year following article publication. Supporting clinical documents including study protocol, statistical analysis plan (SAP), and the informed consent form (ICF) will be available immediately following publication for at least one year. Supporting clinical documents access information will be available at http://www.jshealth.com/. Researchers who provide a scientifically sound proposal will be allowed to access to the individual participant data. Proposals should be directed to jszfc@vip.sina.com or cw0226@foxmail.com.",2020-10-01T09:54:13Z,2020-10-01T09:54:13Z,150
NCT04324606,"ClinicalTrials.gov processed this data on October 05, 2020",2020-03-20,NA,NA,2020-09-30,2020-03-26,2020-03-27,Actual,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-01,Estimate,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,A Study of a Candidate COVID-19 Vaccine (COV001),"A Phase I/II Study to Determine Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19 in UK Healthy Adult Volunteers","Active, not recruiting",NA,Phase 1/Phase 2,1090,Actual,University of Oxford,,14,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-06T08:34:42Z,2020-10-06T08:34:42Z,13
NCT04336410,"ClinicalTrials.gov processed this data on September 30, 2020",2020-04-03,NA,NA,2020-09-18,2020-04-03,2020-04-07,Actual,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-21,Estimate,"April 3, 2020",Actual,2020-04-03,September 2020,2020-09-30,July 2021,Anticipated,2021-07-31,July 2021,Anticipated,2021-07-31,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Phase 1 Open-label Study to Evaluate the Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers","Active, not recruiting",NA,Phase 1,120,Actual,Inovio Pharmaceuticals,,3,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,TRUE,NA,NA,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 10 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be stripped of identifiers and may be made available upon request.,2020-10-01T09:51:21Z,2020-10-01T09:51:21Z,25
NCT04341389,"ClinicalTrials.gov processed this data on September 30, 2020",2020-04-07,NA,NA,2020-05-14,2020-04-09,2020-04-10,Actual,NA,NA,NA,NA,NA,NA,2020-05-14,2020-05-18,Actual,"April 12, 2020",Actual,2020-04-12,May 2020,2020-05-31,"January 31, 2021",Anticipated,2021-01-31,"January 31, 2021",Anticipated,2021-01-31,NA,Interventional,CTII-nCoV,,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years","Active, not recruiting",NA,Phase 2,508,Actual,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:50:37Z,2020-10-01T09:50:37Z,152
NCT04352608,"ClinicalTrials.gov processed this data on September 30, 2020",2020-04-14,NA,NA,2020-08-02,2020-04-16,2020-04-20,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-04,Actual,"April 16, 2020",Actual,2020-04-16,April 2020,2020-04-30,"December 13, 2020",Anticipated,2020-12-13,"July 10, 2020",Actual,2020-07-10,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18~59 Years","Active, not recruiting",NA,Phase 1/Phase 2,744,Actual,"Sinovac Biotech Co., Ltd",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:49:16Z,2020-10-01T09:49:16Z,72
NCT04357028,"ClinicalTrials.gov processed this data on September 30, 2020",2020-04-19,NA,NA,2020-07-15,2020-04-19,2020-04-22,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 13, 2020",Anticipated,2020-07-13,July 2020,2020-07-31,"November 1, 2020",Anticipated,2020-11-01,"October 1, 2020",Anticipated,2020-10-01,NA,Interventional,MV-COVID19,,Measles Vaccine in HCW,Effectiveness of Measles Vaccine in Health Care Professionals During COVID-19 Outbreak (Randomized Controlled Trial),Recruiting,NA,Phase 3,200,Anticipated,Kasr El Aini Hospital,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:48:41Z,2020-10-01T09:48:41Z,90
NCT04368988,"ClinicalTrials.gov processed this data on October 12, 2020",2020-04-24,NA,NA,2020-10-08,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Estimate,"May 25, 2020",Actual,2020-05-25,May 2020,2020-05-31,"November 18, 2021",Anticipated,2021-11-18,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-Mâ„¢ Adjuvant In Healthy Subjects","Active, not recruiting",NA,Phase 1/Phase 2,1419,Actual,Novavax,,10,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-13T08:36:17Z,2020-10-13T08:36:17Z,5
NCT04369794,"ClinicalTrials.gov processed this data on September 30, 2020",2020-04-27,NA,NA,2020-08-05,2020-04-28,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-08-05,2020-08-07,Actual,"August 10, 2020",Anticipated,2020-08-10,August 2020,2020-08-31,August 2023,Anticipated,2023-08-31,June 2021,Anticipated,2021-06-30,NA,Interventional,BATTLE,,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement","COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,NA,Phase 4,1000,Anticipated,"University of Campinas, Brazil",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-10-01T09:47:08Z,2020-10-01T09:47:08Z,69
NCT04368728,"ClinicalTrials.gov processed this data on October 02, 2020",2020-04-27,NA,NA,2020-09-25,2020-04-29,2020-04-30,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Estimate,"April 29, 2020",Actual,2020-04-29,September 2020,2020-09-30,"December 11, 2022",Anticipated,2022-12-11,"June 13, 2021",Anticipated,2021-06-13,NA,Interventional,NA,,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals","A PHASE 1/2/3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINST COVID-19 IN HEALTHY INDIVIDUALS",Recruiting,NA,Phase 2/Phase 3,43998,Anticipated,BioNTech SE,,11,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,Yes,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",2020-10-04T08:43:33Z,2020-10-04T08:43:33Z,18
NCT04380532,"ClinicalTrials.gov processed this data on September 30, 2020",2020-04-29,NA,NA,2020-05-22,2020-05-06,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-05-22,2020-05-27,Actual,"May 15, 2020",Actual,2020-05-15,May 2020,2020-05-31,"June 15, 2021",Anticipated,2021-06-15,"May 15, 2021",Anticipated,2021-05-15,NA,Interventional,COVID-19,,Tableted COVID-19 Therapeutic Vaccine,Clinical Trial of COVID-19 Therapeutic Vaccine Formulated as an Oral Pill,"Active, not recruiting",NA,Phase 1/Phase 2,20,Anticipated,Immunitor LLC,,1,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,when become public,non-confidential data,http://immunitor.com,Yes,Free dissemination of published data,2020-10-01T09:45:46Z,2020-10-01T09:45:46Z,144
NCT04380701,"ClinicalTrials.gov processed this data on September 30, 2020",2020-05-06,NA,NA,2020-09-10,2020-05-07,2020-05-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-10,2020-09-11,Estimate,"April 23, 2020",Actual,2020-04-23,September 2020,2020-09-30,November 2020,Anticipated,2020-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of Four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-2019 Using Different Dosing Regimens in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,456,Anticipated,BioNTech SE,,7,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-10-01T09:45:45Z,2020-10-01T09:45:45Z,33
NCT04383574,"ClinicalTrials.gov processed this data on September 30, 2020",2020-05-09,NA,NA,2020-09-08,2020-05-09,2020-05-12,Actual,NA,NA,NA,NA,NA,NA,2020-09-08,2020-09-10,Estimate,"May 22, 2020",Actual,2020-05-22,May 2020,2020-05-31,"May 30, 2021",Anticipated,2021-05-30,"August 28, 2020",Actual,2020-08-28,NA,Interventional,NA,,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"A Randomized, Double-Blinded, Placebo-Controlled, Phase â… /â…¡ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged â‰¥60 Years","Active, not recruiting",NA,Phase 1/Phase 2,422,Anticipated,"Sinovac Biotech Co., Ltd",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:45:25Z,2020-10-01T09:45:25Z,35
NCT04400838,"ClinicalTrials.gov processed this data on September 30, 2020",2020-05-12,NA,NA,2020-08-21,2020-05-22,2020-05-26,Actual,NA,NA,NA,NA,NA,NA,2020-08-21,2020-08-24,Actual,"May 28, 2020",Actual,2020-05-28,May 2020,2020-05-31,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,Investigating a Vaccine Against COVID-19,"A Phase 2/3 Study to Determine the Efficacy, Safety and Immunogenicity of the Candidate Coronavirus Disease (COVID-19) Vaccine ChAdOx1 nCoV-19",Recruiting,NA,Phase 2/Phase 3,12330,Anticipated,University of Oxford,,24,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:43:12Z,2020-10-01T09:43:12Z,53
NCT04405076,"ClinicalTrials.gov processed this data on September 30, 2020",2020-05-13,NA,NA,2020-07-08,2020-05-26,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-07-08,2020-07-10,Actual,"May 29, 2020",Actual,2020-05-29,July 2020,2020-07-31,August 2021,Anticipated,2021-08-31,March 2021,Anticipated,2021-03-31,NA,Interventional,NA,,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","A Phase 2a, Randomized, Observer-Blind, Placebo Controlled, Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 SARS-COV-2 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",NA,Phase 2,600,Actual,"ModernaTX, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:42:39Z,2020-10-01T09:42:39Z,97
NCT04412538,"ClinicalTrials.gov processed this data on September 30, 2020",2020-05-21,NA,NA,2020-06-02,2020-06-01,2020-06-02,Actual,NA,NA,NA,NA,NA,NA,2020-06-02,2020-06-04,Actual,"May 15, 2020",Actual,2020-05-15,June 2020,2020-06-30,September 2021,Anticipated,2021-09-30,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,"A Randomized, Double-blind, Placebo-controlled, Phase Ia/IIa Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 1/Phase 2,942,Anticipated,Chinese Academy of Medical Sciences,,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:41:41Z,2020-10-01T09:41:41Z,133
NCT04405908,"ClinicalTrials.gov processed this data on September 30, 2020",2020-05-25,NA,NA,2020-06-22,2020-05-25,2020-05-28,Actual,NA,NA,NA,NA,NA,NA,2020-06-22,2020-06-23,Actual,"June 19, 2020",Actual,2020-06-19,June 2020,2020-06-30,"March 30, 2021",Anticipated,2021-03-30,"October 20, 2020",Anticipated,2020-10-20,NA,Interventional,NA,,SCB-2019 as COVID-19 Vaccine,"A Phase 1, Randomized, Double-blind, Placebo-controlled, First-in-human Study to Evaluate the Safety and Immunogenicity of SCB 2019, a Recombinant SARS-CoV-2 Trimeric S Protein Subunit Vaccine for COVID-19 in Healthy Volunteers.",Recruiting,NA,Phase 1,150,Anticipated,Clover Biopharmaceuticals AUS Pty Ltd,,15,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:42:34Z,2020-10-01T09:42:34Z,113
NCT04453852,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-03,NA,NA,2020-06-30,2020-06-30,2020-07-01,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"June 30, 2020",Actual,2020-06-30,June 2020,2020-06-30,"July 1, 2021",Anticipated,2021-07-01,"July 1, 2021",Anticipated,2021-07-01,NA,Interventional,COVAX19,,Monovalent Recombinant COVID19 Vaccine,"A Randomised, Controlled, Phase 1 Study to Evaluate the Safety and Immunogenicity of a Candidate Adjuvanted Recombinant Protein SARS-COV-2 Vaccine in Healthy Adult Subjects",Recruiting,NA,Phase 1,40,Anticipated,Vaxine Pty Ltd,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:36:36Z,2020-10-01T09:36:36Z,105
NCT04444674,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-15,NA,NA,2020-08-02,2020-06-22,2020-06-23,Actual,NA,NA,NA,NA,NA,NA,2020-08-02,2020-08-05,Actual,"June 24, 2020",Actual,2020-06-24,August 2020,2020-08-31,December 2021,Anticipated,2021-12-31,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"An Adaptive Phase I/II Randomized Placebo-controlled Trial to Determine Safety, Immunogenicity and Efficacy of Non-replicating ChAdOx1 SARS-CoV-2 Vaccine in South African Adults Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 1/Phase 2,2000,Anticipated,"University of Witwatersrand, South Africa",,8,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,within 1 year of trial completion,Any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.,NA,Yes,"The data accumulated from this study will be stored at RMPRU/ Wits. In collaboration with UK collaborators, we aim to make the data available, within one year of completion of the study to any investigators who wish to use the data to address any specific questions not directly addressed under the study objectives and which the data would lend itself to.
De-identified data will be shared. Related trial documents will be available (protocol, ICFs, statistical analysis plan)",2020-10-01T09:37:41Z,2020-10-01T09:37:41Z,72
NCT04447781,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-16,NA,NA,2020-08-18,2020-06-24,2020-06-25,Actual,NA,NA,NA,NA,NA,NA,2020-08-18,2020-08-19,Actual,"July 15, 2020",Actual,2020-07-15,August 2020,2020-08-31,"February 22, 2022",Anticipated,2022-02-22,"February 22, 2022",Anticipated,2022-02-22,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19","A Phase I/IIa, Dose-Ranging Trial to Evaluate Safety, Tolerability and Immunogenicity of INO-4800, a Prophylactic Vaccine Against SARS-CoV-2, Administered Intradermally Followed by Electroporation in Healthy Volunteers",Recruiting,NA,Phase 1/Phase 2,160,Anticipated,International Vaccine Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,TRUE,NA,NA,TRUE,NA,,Anonymous IPD may be shared following or during the publication of summary data. Archival data may be accessed for up to 3 years following the end of the study.,Those who request the anonymous IPD must provide a plan of study explaining how the data will be used. Requests may be sent to the Central Contact Person. Requests will be reviewed based on the potential for the planned use of the IPD for advancing scientific knowledge and theory.,NA,Yes,Data dictionaries and all collected IPD will be anonymized and may be made available upon reasonable request.,2020-10-01T09:37:21Z,2020-10-01T09:37:21Z,56
NCT04445194,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-16,NA,NA,2020-06-30,2020-06-21,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-02,Actual,"June 22, 2020",Actual,2020-06-22,May 2020,2020-05-31,"September 20, 2021",Anticipated,2021-09-20,"July 21, 2021",Anticipated,2021-07-21,NA,Interventional,NA,,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Multi-center, Double-blind, Randomized, Placebo Parallel Controlled, Safety and Tolerability Phase I Clinical Trial of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Healthy People Between 18 and 59 Years of Age",Recruiting,NA,Phase 1,50,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:37:38Z,2020-10-01T09:37:38Z,105
NCT04450004,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-18,NA,NA,2020-08-24,2020-06-25,2020-06-29,Actual,NA,NA,NA,NA,NA,NA,2020-08-24,2020-08-25,Actual,"July 10, 2020",Actual,2020-07-10,August 2020,2020-08-31,"April 30, 2021",Anticipated,2021-04-30,"September 12, 2020",Anticipated,2020-09-12,NA,Interventional,NA,,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","A Randomized, Partially-Blinded, Dose-Ranging Phase 1 Study to Assess the Safety, Tolerability, and Immunogenicity of a Recombinant Coronavirus-Like Particle COVID 19 Vaccine in Adults 18-55 Years of Age","Active, not recruiting",NA,Phase 1,180,Anticipated,Medicago,,9,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-10-01T09:37:05Z,2020-10-01T09:37:05Z,50
NCT04449276,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-18,NA,NA,2020-06-30,2020-06-23,2020-06-26,Actual,NA,NA,NA,NA,NA,NA,2020-06-30,2020-07-01,Actual,"June 18, 2020",Actual,2020-06-18,June 2020,2020-06-30,August 2021,Anticipated,2021-08-31,August 2021,Anticipated,2021-08-31,NA,Interventional,NA,,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","A Phase 1, Partially Blind, Placebo-controlled, Dose-escalation, First-in-human, Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity After 1 and 2 Doses of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV Administered Intramuscularly in Healthy Adults",Recruiting,NA,Phase 1,168,Anticipated,CureVac AG,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:37:11Z,2020-10-01T09:37:11Z,105
NCT04445389,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-19,NA,NA,2020-07-24,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-28,Actual,"June 17, 2020",Actual,2020-06-17,July 2020,2020-07-31,"June 17, 2022",Anticipated,2022-06-17,"March 17, 2021",Anticipated,2021-03-17,NA,Interventional,NA,,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults","A Phase 1/2a, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, and Immunogenicity of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Subjects",Recruiting,NA,Phase 1/Phase 2,210,Anticipated,"Genexine, Inc.",,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:37:36Z,2020-10-01T09:37:36Z,81
NCT04445428,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-22,NA,NA,2020-07-15,2020-06-22,2020-06-24,Actual,NA,NA,NA,NA,NA,NA,2020-07-15,2020-07-16,Actual,"July 15, 2020",Actual,2020-07-15,July 2020,2020-07-31,June 2021,Anticipated,2021-06-30,June 2021,Anticipated,2021-06-30,NA,Interventional,NA,,OPV as Potential Protection Against COVID-19,Oral Polio Vaccine as Potential Protection Against COVID-19: A Cluster-randomised Trial in Guinea-Bissau,Enrolling by invitation,NA,Phase 4,3400,Anticipated,Bandim Health Project,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,"Provided request, data can be made available",2020-10-01T09:37:36Z,2020-10-01T09:37:36Z,90
NCT04456595,"ClinicalTrials.gov processed this data on September 30, 2020",2020-06-30,NA,NA,2020-07-31,2020-06-30,2020-07-02,Actual,NA,NA,NA,NA,NA,NA,2020-07-31,2020-08-04,Actual,"July 21, 2020",Actual,2020-07-21,July 2020,2020-07-31,October 2021,Anticipated,2021-10-31,September 2021,Anticipated,2021-09-30,NA,Interventional,PROFISCOV,,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate Efficacy and Safety in Healthcare Professionals of the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac",Recruiting,NA,Phase 3,8870,Anticipated,Butantan Institute,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-10-01T09:36:17Z,2020-10-01T09:36:17Z,74
NCT04461379,"ClinicalTrials.gov processed this data on September 30, 2020",2020-07-02,NA,NA,2020-09-24,2020-07-07,2020-07-08,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-25,Estimate,"July 21, 2020",Actual,2020-07-21,September 2020,2020-09-30,"January 1, 2021",Anticipated,2021-01-01,"January 1, 2021",Anticipated,2021-01-01,NA,Interventional,NA,,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Prevention, Efficacy and Safety of BCG Vaccine in COVID-19- Randomized Clinical Trial",Recruiting,NA,Phase 3,908,Anticipated,Hospital Universitario Dr. Jose E. Gonzalez,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:35:39Z,2020-10-01T09:35:39Z,19
NCT04460703,"ClinicalTrials.gov processed this data on September 30, 2020",2020-07-02,NA,NA,2020-07-18,2020-07-06,2020-07-07,Actual,NA,NA,NA,NA,NA,NA,2020-07-18,2020-07-21,Actual,"July 3, 2020",Actual,2020-07-03,July 2020,2020-07-31,"July 8, 2020",Actual,2020-07-08,"July 8, 2020",Actual,2020-07-08,NA,Interventional,NA,,"COVID-19 Vaccine Messaging, Part 1","Persuasive Messages for COVID-19 Vaccine Uptake: a Randomized Controlled Trial, Part 1",Completed,NA,N/A,4000,Actual,Yale University,,12,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,After publication,Anonymized data and analysis code will be posted in a public replication archive,NA,Yes,Anonymized data and analysis code will be posted in a public replication archive after publication.,2020-10-01T09:35:43Z,2020-10-01T09:35:43Z,87
NCT04466085,"ClinicalTrials.gov processed this data on September 30, 2020",2020-07-08,NA,NA,2020-07-24,2020-07-08,2020-07-10,Actual,NA,NA,NA,NA,NA,NA,2020-07-24,2020-07-27,Actual,"July 12, 2020",Actual,2020-07-12,July 2020,2020-07-31,"December 15, 2021",Anticipated,2021-12-15,"September 15, 2021",Anticipated,2021-09-15,NA,Interventional,NA,,Clinical Study of Recombinant Novel Coronavirus Vaccine,"A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years",Recruiting,NA,Phase 2,900,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:35:05Z,2020-10-01T09:35:05Z,81
NCT04470427,"ClinicalTrials.gov processed this data on October 02, 2020",2020-07-11,NA,NA,2020-09-25,2020-07-11,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-28,Estimate,"July 27, 2020",Actual,2020-07-27,September 2020,2020-09-30,"October 27, 2022",Anticipated,2022-10-27,"October 27, 2022",Anticipated,2022-10-27,NA,Interventional,NA,,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults Aged 18 Years and Older",Recruiting,NA,Phase 3,30000,Anticipated,"ModernaTX, Inc.",,2,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-03T08:49:45Z,2020-10-03T08:49:45Z,18
NCT04495933,"ClinicalTrials.gov processed this data on September 30, 2020",2020-07-13,NA,NA,2020-09-02,2020-07-31,2020-08-03,Actual,NA,NA,NA,NA,NA,NA,2020-09-02,2020-09-04,Estimate,"July 13, 2020",Actual,2020-07-13,July 2020,2020-07-31,September 2021,Anticipated,2021-09-30,October 2020,Anticipated,2020-10-31,NA,Interventional,NA,,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults","A Phase 1, Randomised, Double-Blind, Placebo-Controlled, Dosage-Escalation, Single Centre Study to Evaluate the Safety and Immunogenicity of an Adjuvanted SARS-CoV-2 Sclamp Protein Subunit Vaccine in Healthy Adults Aged 18 to 55 Years Old and Healthy Older Adults, Aged 56 Years and Over",Recruiting,NA,Phase 1,216,Anticipated,The University of Queensland,,3,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,"Immediately following publication, no end date",Available only to achieve the aims in the approved proposal,NA,Yes,individual participant data underlying published results only on a case-by-case basis at the discretion of Primary Sponsor,2020-10-01T09:31:25Z,2020-10-01T09:31:25Z,41
NCT04470609,"ClinicalTrials.gov processed this data on September 30, 2020",2020-07-13,NA,NA,2020-07-13,2020-07-13,2020-07-14,Actual,NA,NA,NA,NA,NA,NA,2020-07-13,2020-07-14,Actual,"July 10, 2020",Actual,2020-07-10,July 2020,2020-07-31,November 2021,Anticipated,2021-11-30,November 2020,Anticipated,2020-11-30,NA,Interventional,NA,,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,"A Randomized, Double-blind, Placebo-controlled, Phase Ib/IIb Trial of an Inactivated SARS-CoV-2 Vaccine in Healthy People Aged â©¾60 Years",Enrolling by invitation,NA,Phase 1/Phase 2,471,Anticipated,Chinese Academy of Medical Sciences,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:34:31Z,2020-10-01T09:34:31Z,92
NCT04475302,"ClinicalTrials.gov processed this data on September 30, 2020",2020-07-16,NA,NA,2020-07-21,2020-07-16,2020-07-17,Actual,NA,NA,NA,NA,NA,NA,2020-07-21,2020-07-23,Actual,"July 1, 2020",Actual,2020-07-01,July 2020,2020-07-31,May 2021,Anticipated,2021-05-31,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Study to Evaluate the Effectiveness of BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots in India,Recruiting,NA,Phase 3,2175,Anticipated,"Tuberculosis Research Centre, India",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:34:00Z,2020-10-01T09:34:00Z,84
NCT04497298,"ClinicalTrials.gov processed this data on October 02, 2020",2020-07-31,NA,NA,2020-09-24,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Estimate,"August 10, 2020",Actual,2020-08-10,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,November 2020,Anticipated,2020-11-30,NA,Interventional,COVID-19-101,,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"A Randomized, Placebo-controlled Trial, to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine, a Measles Vector-based Vaccine Candidate Against COVID-19 in Healthy Volunteers Consisting of an Unblinded Dose Escalation and a Blinded Treatment Phase",Recruiting,NA,Phase 1,90,Anticipated,Institut Pasteur,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-03T08:49:10Z,2020-10-03T08:49:10Z,19
NCT04510207,"ClinicalTrials.gov processed this data on October 12, 2020",2020-08-03,NA,NA,2020-10-07,2020-08-10,2020-08-12,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-08,Estimate,"July 16, 2020",Actual,2020-07-16,October 2020,2020-10-31,"September 16, 2021",Anticipated,2021-09-16,"March 16, 2021",Anticipated,2021-03-16,NA,Interventional,COVID-19,,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above","Multicenter, Randomized, Double Blind, Parallel Placebo Controlled, Phase III Clinical Trial to Evaluate the Protective Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,NA,Phase 3,45000,Anticipated,China National Biotec Group Company Limited,,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-13T08:34:15Z,2020-10-13T08:34:15Z,6
NCT04498247,"ClinicalTrials.gov processed this data on October 12, 2020",2020-08-03,NA,NA,2020-10-08,2020-08-03,2020-08-04,Actual,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Estimate,"August 27, 2020",Actual,2020-08-27,October 2020,2020-10-31,"April 26, 2022",Anticipated,2022-04-26,"April 26, 2022",Anticipated,2022-04-26,NA,Interventional,NA,,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)","A Phase 1/Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety, Tolerability and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Younger and Older Participants",Recruiting,NA,Phase 1/Phase 2,260,Anticipated,Merck Sharp & Dohme Corp.,,6,NA,NA,NA,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,http://engagezone.msd.com/ds_documentation.php,Yes,http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf,2020-10-13T08:34:25Z,2020-10-13T08:34:25Z,5
NCT04508075,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-07,NA,NA,2020-08-20,2020-08-08,2020-08-11,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,September 2021,Anticipated,2021-09-30,January 2021,Anticipated,2021-01-31,NA,Interventional,COVID-19,,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","A Phase III, Observer-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Inactivated Vaccine in Healthy Adults Aged 18-59 Years in Indonesia",Recruiting,NA,Phase 3,1620,Anticipated,PT Bio Farma,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-10-01T09:29:51Z,2020-10-01T09:29:51Z,54
NCT04527575,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-11,NA,NA,2020-09-21,2020-08-25,2020-08-26,Actual,NA,NA,NA,NA,NA,NA,2020-09-21,2020-09-22,Estimate,"July 27, 2020",Actual,2020-07-27,August 2020,2020-08-31,"October 4, 2020",Anticipated,2020-10-04,"September 28, 2020",Anticipated,2020-09-28,NA,Interventional,EpiVacCorona,,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Simple, Blind, Placebo-controlled, Randomized Study of the Safety, Reactogenicity and Immunogenicity of Vaccine Based on Peptide Antigens for the Prevention of COVID-19 (EpiVacCorona), in Volunteers Aged 18-60 Years (I-II Phase)","Active, not recruiting",NA,Phase 1/Phase 2,100,Actual,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",,3,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:27:29Z,2020-10-01T09:27:29Z,22
NCT04522089,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-12,NA,NA,2020-09-22,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-24,Estimate,"August 24, 2020",Actual,2020-08-24,August 2020,2020-08-31,"March 20, 2021",Anticipated,2021-03-20,"November 20, 2020",Anticipated,2020-11-20,NA,Interventional,NA,,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,"A Randomized, Single Center, Open-label, Dose-finding, Phase I Study to Evaluate the Safety and Immunogenicity of Pandemic Virus Vaccine, AdimrSC-2f (SARS-CoV-2), in Healthy Volunteers",Recruiting,NA,Phase 1,70,Anticipated,Adimmune Corporation,,4,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:28:10Z,2020-10-01T09:28:10Z,21
NCT04515147,"ClinicalTrials.gov processed this data on October 12, 2020",2020-08-13,NA,NA,2020-10-07,2020-08-13,2020-08-17,Actual,NA,NA,NA,NA,NA,NA,2020-10-07,2020-10-09,Estimate,"September 28, 2020",Actual,2020-09-28,August 2020,2020-08-31,"November 9, 2021",Anticipated,2021-11-09,"November 9, 2021",Anticipated,2021-11-09,NA,Interventional,NA,,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age",Recruiting,NA,Phase 2,691,Anticipated,CureVac AG,,10,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-13T08:34:08Z,2020-10-13T08:34:08Z,6
NCT04550351,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-16,NA,NA,2020-09-14,2020-09-14,2020-09-15,Estimate,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-15,Estimate,"August 19, 2020",Actual,2020-08-19,August 2020,2020-08-31,"December 31, 2021",Anticipated,2021-12-31,"October 31, 2021",Anticipated,2021-10-31,NA,Interventional,NA,,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety and Tolerability of Recombinant New Coronavirus Vaccines (CHO Cells) in Healthy People Aged 60 Years and Above",Recruiting,NA,Phase 1/Phase 2,50,Anticipated,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",,3,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:24:45Z,2020-10-01T09:24:45Z,29
NCT04540419,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-17,NA,NA,2020-09-15,2020-09-04,2020-09-07,Estimate,NA,NA,NA,NA,NA,NA,2020-09-15,2020-09-17,Estimate,"September 11, 2020",Actual,2020-09-11,September 2020,2020-09-30,"July 31, 2021",Anticipated,2021-07-31,"November 30, 2020",Anticipated,2020-11-30,NA,Interventional,NA,,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group Study Evaluating Efficacy, Reactogenicity and Safety of Recombinant Vaccine Ad5-nCoV Against Novel Coronavirus Infection in Adult Volunteers",Recruiting,NA,Phase 3,500,Anticipated,NPO Petrovax,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-01T09:25:58Z,2020-10-01T09:25:58Z,28
NCT04523571,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-18,NA,NA,2020-08-20,2020-08-20,2020-08-21,Actual,NA,NA,NA,NA,NA,NA,2020-08-20,2020-08-21,Actual,"July 28, 2020",Actual,2020-07-28,August 2020,2020-08-31,August 2021,Anticipated,2021-08-31,September 2020,Anticipated,2020-09-30,NA,Interventional,NA,,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects: A Phase I, Randomized, Placebo-controlled, Observer-blind Study",Recruiting,NA,Phase 1,144,Anticipated,BioNTech SE,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:28:00Z,2020-10-01T09:28:00Z,54
NCT04528641,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-19,NA,NA,2020-08-27,2020-08-25,2020-08-27,Actual,NA,NA,NA,NA,NA,NA,2020-08-27,2020-08-31,Actual,"August 10, 2020",Actual,2020-08-10,August 2020,2020-08-31,"July 31, 2021",Anticipated,2021-07-31,"July 31, 2021",Anticipated,2021-07-31,NA,Interventional,NA,,GRAd-COV2 Vaccine Against COVID-19,"A Phase 1, Dosage-Escalation Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine GRAd-COV2 in Healthy Adults and Elderly Subjects",Recruiting,NA,Phase 1,90,Anticipated,ReiThera Srl,,6,NA,NA,FALSE,NA,NA,NA,NA,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,NA,2020-10-01T09:27:23Z,2020-10-01T09:27:23Z,47
NCT04568031,"ClinicalTrials.gov processed this data on October 02, 2020",2020-08-21,NA,NA,2020-09-25,2020-09-25,2020-09-29,Estimate,NA,NA,NA,NA,NA,NA,2020-09-25,2020-09-29,Estimate,"August 23, 2020",Actual,2020-08-23,September 2020,2020-09-30,"September 6, 2021",Anticipated,2021-09-06,"September 6, 2021",Anticipated,2021-09-06,NA,Interventional,NA,,Study of AZD1222 for the Prevention of COVID-19 in Japan,"A Phase I/II Randomized, Double-blind, Placebo-controlled Multicentre Study in Participants Aged 18 Years or Older to Determine the Safety and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19",Recruiting,NA,Phase 1/Phase 2,12,Anticipated,AstraZeneca,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,NA,NA,,"AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure","When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure",https://astrazenecagroup-dt.pharmacm.com/DT/Home,Yes,Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure,2020-10-04T08:38:45Z,2020-10-04T08:38:45Z,18
NCT04530396,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-25,NA,NA,2020-09-22,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-22,2020-09-23,Estimate,"September 7, 2020",Actual,2020-09-07,August 2020,2020-08-31,"May 1, 2021",Anticipated,2021-05-01,"May 1, 2021",Anticipated,2021-05-01,NA,Interventional,RESIST,,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Randomized Double-blind Placebo-controlled Multi-center Clinical Trial in Parallel Assignment of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine in SARS-Ð¡oV-2 Infection Prophylactic Treatment",Recruiting,NA,Phase 3,40000,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:27:10Z,2020-10-01T09:27:10Z,21
NCT04530357,"ClinicalTrials.gov processed this data on October 02, 2020",2020-08-26,NA,NA,2020-09-29,2020-08-27,2020-08-28,Actual,NA,NA,NA,NA,NA,NA,2020-09-29,2020-09-30,Estimate,"September 19, 2020",Actual,2020-09-19,August 2020,2020-08-31,"April 30, 2021",Anticipated,2021-04-30,"December 1, 2020",Anticipated,2020-12-01,NA,Interventional,NA,,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine","Randomized, Blind, Placebo-controlled Phase- i Study and Randomized, Open Phase Phase-ii Study of QAZCOVID-INÂ®- COVID-19 Inactivated Vaccine in Healthy Adult Volunteers From 18 Years Old and Elder",Enrolling by invitation,NA,Phase 1/Phase 2,244,Anticipated,Research Institute for Biological Safety Problems,,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-05T08:31:52Z,2020-10-05T08:31:52Z,14
NCT04533399,"ClinicalTrials.gov processed this data on September 30, 2020",2020-08-28,NA,NA,2020-08-28,2020-08-28,2020-08-31,Actual,NA,NA,NA,NA,NA,NA,2020-08-28,2020-08-31,Actual,"August 17, 2020",Actual,2020-08-17,August 2020,2020-08-31,November 2021,Anticipated,2021-11-30,November 2021,Anticipated,2021-11-30,NA,Interventional,NA,,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,"A Phase 2A/B, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in South African Adult Subjects Living Without HIV; and Safety and Immunogenicity in Adults Living With HIV",Recruiting,NA,Phase 2,2904,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-10-01T09:26:47Z,2020-10-01T09:26:47Z,46
NCT04537949,"ClinicalTrials.gov processed this data on September 30, 2020",2020-09-02,NA,NA,2020-09-14,2020-09-02,2020-09-03,Estimate,NA,NA,NA,NA,NA,NA,2020-09-14,2020-09-15,Estimate,"September 9, 2020",Actual,2020-09-09,September 2020,2020-09-30,December 2021,Anticipated,2021-12-31,September 2021,Anticipated,2021-09-30,NA,Interventional,NA,,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"A Multi-site, Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of a Prophylactic SARS-CoV-2 RNA Vaccine (BNT162b3) Against COVID-19 Using Different Dosing Regimens in Healthy Adults",Recruiting,NA,Phase 1/Phase 2,120,Anticipated,BioNTech SE,,2,NA,NA,FALSE,NA,NA,NA,FALSE,FALSE,FALSE,NA,NA,FALSE,NA,,NA,NA,NA,No,NA,2020-10-01T09:26:15Z,2020-10-01T09:26:15Z,29
NCT04537208,"ClinicalTrials.gov processed this data on September 30, 2020",2020-09-02,NA,NA,2020-09-18,2020-09-02,2020-09-03,Estimate,NA,NA,NA,NA,NA,NA,2020-09-18,2020-09-21,Estimate,"September 3, 2020",Actual,2020-09-03,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,October 2021,Anticipated,2021-10-31,NA,Interventional,NA,,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,Immunogenicity and Safety of SARS-CoV-2 Recombinant Protein Vaccine Formulations (With or Without Adjuvant) in Healthy Adults 18 Years of Age and Older,Recruiting,NA,Phase 1/Phase 2,440,Anticipated,Sanofi,,21,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Yes,"Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/",2020-10-01T09:26:21Z,2020-10-01T09:26:21Z,25
NCT04540185,"ClinicalTrials.gov processed this data on September 30, 2020",2020-09-04,NA,NA,2020-09-05,2020-09-04,2020-09-07,Estimate,NA,NA,NA,NA,NA,NA,2020-09-05,2020-09-09,Estimate,"November 1, 2020",Anticipated,2020-11-01,September 2020,2020-09-30,"December 31, 2022",Anticipated,2022-12-31,"November 1, 2022",Anticipated,2022-11-01,NA,Interventional,OPV-NA831,,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,"A Phase 3, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Polio Vaccine and NA-831 for Prophylaxis and Treatment of Early Onset of Covid-19",Enrolling by invitation,NA,Phase 3,3600,Anticipated,"NeuroActiva, Inc.",,6,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,NA,NA,,90 days after completion of the study,To be verified and determined at a later date,NA,Yes,We plan to share the Study Protocol and other information if needed,2020-10-01T09:26:00Z,2020-10-01T09:26:00Z,38
NCT04552366,"ClinicalTrials.gov processed this data on September 30, 2020",2020-09-15,NA,NA,2020-09-20,2020-09-16,2020-09-17,Estimate,NA,NA,NA,NA,NA,NA,2020-09-20,2020-09-23,Estimate,"September 29, 2020",Anticipated,2020-09-29,September 2020,2020-09-30,"June 30, 2021",Anticipated,2021-06-30,"December 31, 2020",Anticipated,2020-12-31,NA,Interventional,NA,,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,A Clinical Trial to Evaluate the Safety and Immunogenicity of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults Aged 18 Years and Older,Recruiting,NA,Phase 1,144,Anticipated,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",,6,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-01T09:24:32Z,2020-10-01T09:24:32Z,23
NCT04560881,"ClinicalTrials.gov processed this data on October 06, 2020",2020-09-16,NA,NA,2020-09-30,2020-09-21,2020-09-23,Estimate,NA,NA,NA,NA,NA,NA,2020-09-30,2020-10-02,Estimate,"September 16, 2020",Actual,2020-09-16,September 2020,2020-09-30,"December 1, 2021",Anticipated,2021-12-01,"December 1, 2021",Anticipated,2021-12-01,NA,Interventional,NA,,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Randomized, Double Blind, Placebo Parallel-controlled Phase III Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (Vero Cell) in Argentine Healthy Population Aged Between 18 and 85 Years",Recruiting,NA,Phase 3,3000,Anticipated,Laboratorio Elea Phoenix S.A.,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-07T08:33:15Z,2020-10-07T08:33:15Z,13
NCT04563702,"ClinicalTrials.gov processed this data on October 02, 2020",2020-09-21,NA,NA,2020-09-24,2020-09-23,2020-09-24,Estimate,NA,NA,NA,NA,NA,NA,2020-09-24,2020-09-28,Estimate,September 2020,Anticipated,2020-09-30,September 2020,2020-09-30,October 2021,Anticipated,2021-10-31,December 2020,Anticipated,2020-12-31,NA,Interventional,NA,,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"A Phase 1 Open-Label, Dose-Ranging Trial to Determine the Safety and Immunogenicity of an Adenoviral-Vector Based Vaccine (VXA-CoV2-1) Expressing a SARS-CoV-2 Antigen and dsRNA Adjuvant Administered Orally to Healthy Adult Volunteers",Recruiting,NA,Phase 1,48,Anticipated,Vaxart,,2,NA,NA,FALSE,NA,NA,NA,FALSE,TRUE,FALSE,NA,NA,NA,NA,,NA,NA,NA,Undecided,A plan on how to share individual subject's outcomes will be defined within the next few months.,2020-10-03T08:47:11Z,2020-10-03T08:47:11Z,19
NCT04564716,"ClinicalTrials.gov processed this data on October 05, 2020",2020-09-24,NA,NA,2020-09-29,2020-09-24,2020-09-25,Estimate,NA,NA,NA,NA,NA,NA,2020-09-29,2020-10-01,Estimate,"September 28, 2020",Actual,2020-09-28,September 2020,2020-09-30,"April 10, 2021",Anticipated,2021-04-10,"March 28, 2021",Anticipated,2021-03-28,NA,Interventional,NA,,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Ð¡linical Trial of Efficacy, Safety and Immunogenicity of Combined Vector Vaccine Gam-COVID-Vac in SARS-Ð¡oV-2 Infection Prophylactic Treatment in Republic of Belarus",Recruiting,NA,Phase 3,100,Anticipated,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,NA,NA,2020-10-06T08:30:54Z,2020-10-06T08:30:54Z,14
NCT04568811,"ClinicalTrials.gov processed this data on October 02, 2020",2020-09-28,NA,NA,2020-09-28,2020-09-28,2020-09-29,Estimate,NA,NA,NA,NA,NA,NA,2020-09-28,2020-09-29,Estimate,"September 26, 2020",Actual,2020-09-26,September 2020,2020-09-30,"September 27, 2021",Anticipated,2021-09-27,"October 25, 2020",Anticipated,2020-10-25,NA,Interventional,NA,,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"The Single-center, Open-label Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine in Healthy Adults Aged 18-60 Years","Active, not recruiting",NA,Phase 1,89,Actual,Jiangsu Province Centers for Disease Control and Prevention,,1,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-04T08:38:16Z,2020-10-04T08:38:16Z,15
NCT04582344,"ClinicalTrials.gov processed this data on October 12, 2020",2020-10-01,NA,NA,2020-10-08,2020-10-08,2020-10-09,Estimate,NA,NA,NA,NA,NA,NA,2020-10-08,2020-10-09,Estimate,"September 14, 2020",Actual,2020-09-14,October 2020,2020-10-31,"April 15, 2021",Anticipated,2021-04-15,"February 15, 2021",Anticipated,2021-02-15,NA,Interventional,NA,,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),"Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated",Recruiting,NA,Phase 3,13000,Anticipated,Health Institutes of Turkey,,2,NA,NA,FALSE,NA,NA,NA,TRUE,FALSE,FALSE,NA,NA,NA,NA,,NA,NA,NA,No,NA,2020-10-13T08:30:35Z,2020-10-13T08:30:35Z,5
NCT04583995,"ClinicalTrials.gov processed this data on October 12, 2020",2020-10-09,NA,NA,2020-10-09,2020-10-09,2020-10-12,Estimate,NA,NA,NA,NA,NA,NA,2020-10-09,2020-10-12,Estimate,"September 28, 2020",Actual,2020-09-28,October 2020,2020-10-31,"January 14, 2022",Anticipated,2022-01-14,January 2021,Anticipated,2021-01-31,NA,Interventional,NA,,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","A Phase 3, Randomised, Observer-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1â„¢ Adjuvant in Adult Participants 18-84 Years of Age in the United Kingdom",Recruiting,NA,Phase 3,9000,Anticipated,Novavax,,4,NA,NA,FALSE,NA,NA,NA,TRUE,TRUE,FALSE,NA,NA,TRUE,NA,,NA,NA,NA,No,NA,2020-10-13T08:29:35Z,2020-10-13T08:29:35Z,4
